Piracetam
Cognitive · Racetam
Tier B
Bottom line
Read Off Label grades Piracetam as B (6.4/10) based on weak-moderate evidence, variable benefit magnitude, and a low-risk safety profile.
Gouhie 2024 meta-analysis in adults with memory impairment could not definitively establish an effect on memory (heterogeneous data).
Studied, labeled, or reported-use context: 1. — Rx in EU; unscheduled research chem in US; not individualized guidance.
Frontier potential — editorial judgment, not evidence
This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.
What the ceiling rests on
The original nootropic, with a very large accumulated literature, decades of European clinical use, and a benign safety record — the most-studied compound in its class by a wide margin.
Why it may not get there
The volume of literature is not matched by its quality: results in healthy adults are weak and inconsistent, the better-designed trials are in cognitive impairment and dyslexia rather than enhancement, and Cochrane-style syntheses have not supported a cognitive-enhancement claim. Decades of study without a clear positive is itself informative — this is closer to a settled negative than an open question.
What would change this None pending — the enhancement question has largely been asked and answered.
What the evidence says
Gouhie 2024 meta-analysis in adults with memory impairment could not definitively establish an effect on memory (heterogeneous data). Older 2002 Waegemans meta found modest global benefit in elderly cognitive impairment. Approved in many EU countries for cortical myoclonus and age-related cognitive decline. Generally very well tolerated.
Mechanism
Parent racetam; modulates AMPA and NMDA receptor function; increases membrane fluidity; enhances cerebral blood flow and glucose utilization; mechanism not fully characterized
Studied, labeled, or reported dose & route
1.6-4.8 g/day PO in divided doses; attack dose up to 9.6 g/day
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Piracetam's effects?
- Read Off Label rates the evidence for Piracetam as Weak-Moderate and the benefit magnitude as variable, producing an overall grade of B (6.4/10). Gouhie 2024 meta-analysis in adults with memory impairment could not definitively establish an effect on memory (heterogeneous data).
- What safety findings are reported for Piracetam?
- Piracetam has a low risk profile in the database. Low Legal status: Rx in EU; unscheduled research chem in US (not FDA-approved).
- What doses or routes are reported for Piracetam?
- 1.6-4.8 g/day PO in divided doses; attack dose up to 9.6 g/day This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Piracetam work?
- Parent racetam; modulates AMPA and NMDA receptor function; increases membrane fluidity; enhances cerebral blood flow and glucose utilization; mechanism not fully characterized
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.